Development of cyclosporine A nanosuspension: cytotoxicity and permeability on Caco-2 cell lines

References

• Ağardan NBM, Değim Z, Yılmaz Ş, Altıntaş L, Topal T. 2020. Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer. J Drug Deliv Sci Technol. 57:101612.
   Web of Science ®Google Scholar
• Ahire E, Thakkar S, Darshanwad M, Misra M. 2018. Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications. Acta Pharm Sin B. 8(5):733–755.
   PubMed Web of Science ®Google Scholar
• Al-Heibshy FNS, Başaran E, Arslan R, Öztürk N, Vural İ, Demirel M. 2019. Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin–polyanhydride nanoparticles. Drug Dev Ind Pharm. 45(10):1635–1645.
   PubMed Web of Science ®Google Scholar
• Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 175(3):880–885.
   PubMed Web of Science ®Google Scholar
• Attari Z, Bhandari A, Jagadish PC, Lewis S. 2016. Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: preparation by combinative technology. Saudi Pharm J. 24(1):57–63.
   PubMed Web of Science ®Google Scholar
• Bilgili E, Li M, Afolabi A. 2016. Is the combination of cellulosic polymers and anionic surfactants a good strategy for ensuring physical stability of BCS Class II drug nanosuspensions? Pharm Dev Technol. 21(4):499–510.
   PubMed Web of Science ®Google Scholar
• Budavari SM, O’Neal J, Smith A, Heckelman PE. 1996. The Merck Index: an encyclopedia of chemicals, drugs and biologicals. 12th ed. Whitehouse Station (NJ): Merck & Company, Inc.; p. 1498.
   Google Scholar
• Çelik Tekeli M, Aktas Y, Celebi N. 2021. Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer. Amino Acids. 53(1):73–88.
   PubMed Web of Science ®Google Scholar
• Föger F, Kopf A, Loretz B, Albrecht K, Bernkop Schnürch A. 2008. Correlation of in vitro and in vivo models for the oral absorption of peptide drugs. Amino Acids. 35(1):233–241.
   PubMed Web of Science ®Google Scholar
• Ghosh I, Schenck D, Bose S, Liu F, Motto M. 2013. Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology—a QbD perspective. Pharm Dev Technol. 18(3):719–729.
   PubMed Web of Science ®Google Scholar
• Gökbulut E, Vural İ, Aşıkoğlu M, Özdemir N. 2019. Floating drug delivery system of itraconazole: formulation, in vitro and in vivo studies. J Drug Deliv Sci Technol. 49:491–501.
   Web of Science ®Google Scholar
• Guada M, Beloqui A, Kumar MNVR, Préat V, Dios-Viéitez MDC, Blanco-Prieto MJ. 2016. Reformulating cyclosporine A (CsA): more than just a life cycle management strategy. J Control Release. 225:269–282.
   PubMed Web of Science ®Google Scholar
• Gülbağ Pınar S, Çelebi N. 2019a. Cyclosporine A nanosuspension produced by wet media milling method: development and characterization. EUFEPS Annual Meeting 2019; Mar 6–8; Germany. Flash presentation-05.
   Google Scholar
• Gülbağ Pınar S, Çelebi N. 2019b. Optimization and evaluation of cyclosporine A nanosuspension stabilized by combination stabilizers using high pressure homogenization method. J Res Pharm. 23:1009–1021.
   Google Scholar
• Gülbağ Pınar S, Karaküçük A, Mutlu Ağardan N, Çelebi N. 2019a. The effects of process parameters of the cyclosporine A nanosuspension produced by wet milling stabilized with hydroxypropyl methylcellulose. CRS Annual Meeting 2019; Jul 21–24; Spain. Poster session II. p. 657.
   Google Scholar
• Gülbağ Pınar S, Mutlu Ağardan B, Çelebi N. 2019b. Evaluation of dissolution properties of cyclosporine A nanosuspensions prepared with two different top down technologies. The 8th BBBB International Conference on Pharmaceutical Sciences; Oct 14–16; Turkey. Oral presentations-6.
   Google Scholar
• Gülbağ S, Çelebi N. 2017. Cyclosporine A and new approaches to cyclosporine A formulations. FABAD J Pharm Sci. 42:39–58.
   Google Scholar
• Gulsun T, Borna SE, Vural I, Sahin S. 2018. Preparation and characterization of furosemide nanosuspensions. J Drug Deliv Sci Technol. 45:93–100.
   Web of Science ®Google Scholar
• Gulsun T, Ozturk N, Kaynak MS, Vural I, Sahin S. 2017. Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression. Pharmazie. 72(7):389–394.
   PubMed Web of Science ®Google Scholar
• Hautz T, Brandacher G, Zelger B, Gorantla VS, Lee AW, Pratschke J, Schneeberger S. 2010. Immunologic aspects and rejection in solid organ versus reconstructive transplantation. Transplant Proc. 42(9):3347–3353.
   PubMed Web of Science ®Google Scholar
• He J, Han Y, Xu G, Yin L, Ngandeu NM, Zhou J, Ding Y. 2017. Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement. RSC Adv. 7(22):13053–13064.
   Web of Science ®Google Scholar
• Junghanns JU, Müller RH. 2008. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 3(3):295–309.
   PubMed Web of Science ®Google Scholar
• Junyaprasert VB, Morakul B. 2015. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 10(1):13–23.
   Web of Science ®Google Scholar
• Karakucuk A, Celebi N. 2020. Investigation of formulation and process parameters of wet media milling to develop etodolac nanosuspensions. Pharm Res. 37(6):111.
   PubMed Web of Science ®Google Scholar
• Karakucuk A, Celebi N, Teksin ZS. 2016. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A design of experiment approach. Eur J Pharm Sci. 95:111–121.
   PubMed Web of Science ®Google Scholar
• Karakucuk A, Ozturk N, Celebi N. 2020b. Evaluation of Caco-2 cell permeability of ritonavir nanosuspensions. Istanbul J Pharm. 50(3):251–255.
   Web of Science ®Google Scholar
• Karakucuk A, Tashan E, Ozturk N, Celebi N. 2020a. In vitro Caco-2 cell permeability studies of ziprasidone hydrochloride monohydrate nanocrystals. Turk J Pharm Sci. 18(2):223–227.
   Web of Science ®Google Scholar
• Karamustafa F, Celebi N, Değim Z, Unal N. 2009. Transport evaluation of alendronate across Caco-2 cell monolayers. Pharmazie. 64(2):98–103.
   PubMed Web of Science ®Google Scholar
• Kocbek P, Baumgartner S, Kristl J. 2006. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm. 312(1–2):179–186.
   PubMed Web of Science ®Google Scholar
• Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L, Zhang Y, Fang L. 2011. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 408(1–2):157–162.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Yang J, Zhang H, Gan L. 2019. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: prolonged ocular retention, enhanced corneal permeation and improved tear production. Int J Pharm. 565:133–142.
   PubMedGoogle Scholar
• Ma B, Wang J, Sun J, Li M, Xu H, Sun G, Sun X. 2014. Permeability of rhynchophylline across human intestinal cell in vitro. Int J Clin Exp Pathol. 7(5):1957–1966.
   PubMed Web of Science ®Google Scholar
• Malaekeh-Nikouei B, Nassirli H, Davies N. 2007. Enhancement of cyclosporine aqueous solubility using α- and hydroxypropyl β-cyclodextrin mixtures. J Incl Phenom Macrocycl Chem. 59(3–4):245–250.
   Web of Science ®Google Scholar
• Malamatari M, Taylor KMG, Malamataris S, Douroumis D, Kachrimanis K. 2018. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today. 23(3):534–547.
   PubMed Web of Science ®Google Scholar
• Mauludin R, Müller RH, Keck CM. 2009. Development of an oral rutin nanocrystal formulation. Int J Pharm. 370(1–2):202–209.
   PubMed Web of Science ®Google Scholar
• Medarevic D, Djuris J, Ibric S, Mitric M, Kachrimanis K. 2018. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling. Int J Pharm. 540(1–2):150–161.
   PubMed Web of Science ®Google Scholar
• Modra L, Hilton A. 2015. Ethical issues in organ transplantation. Anaesth Intens Care Med. 16(7):321–323.
   Web of Science ®Google Scholar
• Nakarani M, Patel P, Patel J, Patel P, Murthy RSR, Vaghani SS. 2010. Cyclosporine A-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sci Pharm. 78(2):345–361.
   PubMedGoogle Scholar
• Oktay AN, Ilbasmis-Tamer S, Celebi N. 2019. The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions. Pharm Dev Technol. 24(10):1278–1286.
   PubMed Web of Science ®Google Scholar
• Oktay AN, Ilbasmis-Tamer S, Han S, Uludag O, Celebi N. 2020. Preparation and in vitro/in vivo evaluation of flurbiprofen nanosuspension-based gel for dermal application. Eur J Pharm Sci. 155:105548.
   PubMed Web of Science ®Google Scholar
• Patel VR, Agrawal YK. 2011. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2(2):81–87.
   PubMedGoogle Scholar
• Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. 2014. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release. 183:51–66.
   PubMed Web of Science ®Google Scholar
• Sakai R, Ooba Y, Watanabe A, Nakamura H, Kawamata Y, Shimada T, Takumi A, van Goudoever JB, Narita T. 2020. Glutamate metabolism in a human intestinal epithelial cell layer model. Amino Acids. 52(11–12):1505–1519.
   PubMed Web of Science ®Google Scholar
• Shekhawat P, Pokharkar V. 2019. Risk assessment and QbD based optimization of an eprosartan mesylate nanosuspension: in-vitro characterization, PAMPA and in-vivo assessment. Int J Pharm. 567:118415.
   PubMed Web of Science ®Google Scholar
• Sinha B, Müller RH, Moschwitzer JP. 2013. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 453(1):126–141.
   PubMedGoogle Scholar
• Survase SA, Kagliwal LD, Annapure US, Singhal RS. 2011. Cyclosporin A—a review on fermentative production, downstream processing and pharmacological applications. Biotechnol Adv. 29(4):418–435.
   PubMed Web of Science ®Google Scholar
• Taymouri S, Ahmadi Z, Mirian M, Tavakoli N. 2021. Simvastatin nanosuspensions prepared using a combination of pH-sensitive and timed-release approaches for potential treatment of colorectal cancer. Pharm Dev Technol. 26(3):335–348.
   PubMed Web of Science ®Google Scholar
• Toziopoulou F, Malamatari M, Nikolakakis I, Kachrimanis K. 2017. Production of aprepitant nanocrystals by wet media milling and subsequent solidification. Int J Pharm. 533(2):324–334.
   PubMed Web of Science ®Google Scholar
• Verma V, Jasuja S. 2008. Current immunosuppression drugs used in transplant: classification & status. Apollo Med. 5(4):373–376.
   Google Scholar
• Wenger RM, Payne TG, Schreier MH. 1986. Cyclosporine: chemistry, structure-activity relationships and mode of action. In: Metabolic control in diabetes mellitus beta adrenoceptor blocking drugs NMR analysis of cancer cells immunoassay in the clinical laboratory cyclosporine. Progress in Clinical Biochemistry and Medicine, vol 3. Berlin, Heidelberg: Springer; p. 157–191.
   Google Scholar
• Wu CY, Benet L. 2005. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 22(1):11–23.
   PubMed Web of Science ®Google Scholar
• Yavuz B, Bilensoy E, Vural I, Sumnu M. 2010. Alternative oral exemestane formulation: improved dissolution and permeation. Int J Pharm. 398(1–2):137–145.
   PubMedGoogle Scholar
• Yue PF, Li Y, Wan J, Yang M, Zhu WF, Wang CH. 2013. Study on formability of solid nanosuspensions during nanodispersion and solidification: I. Novel role of stabilizer/drug property. Int J Pharm. 454(1):269–277.
   PubMed Web of Science ®Google Scholar